mifamurtide

mifamurtide

A fully synthetic lipophilic derivative of muramyl dipeptide, which is an immune stimulatory component of cell walls from Mycobacterium, used to manage high-grade, non-metastasising, resectable osteosarcoma after surgical excision in children to young adults (age 2 to 30).
 
Adverse effects
Fever (90%), tachycardia (50%), constipation (10%), vomiting, fatigue, infections, anaemia, anorexia, headache, diarrhoea.

Prognosis
Mifamurtide-treated patients have a 30% lower mortality than those treated with chemotherapy.
References in periodicals archive ?
Interferon alpha and Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact[R]) have been tried as adjuvants in treatment of osteosarcoma with encouraging results of improved DFS disease-free survival (DFS) of 7%.
The analysis of Mifamurtide was not only challenging, owing to the physical and chemical properties of the molecular entities themselves, but were compounded by the need for a transition from older methods to new ones that met current standards .
Mifamurtide, if made commercially available, will provide treating physicians with a new tool with significant potential to improve patient outcome and, most importantly, survival.
Appraisal consultation document - Mifamurtide for the treatment of osteosarcoma.
The availability of mifamurtide brings hope to children and young adults in need of a more positive treatment option for this devastating disease.
We look forward to amending the New Drug Application (NDA) for mifamurtide in the United States and continuing to work toward bringing this important treatment to market in the U.
Nasdaq: IDMI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion, recommending grant of a centralized marketing authorization for mifamurtide (L-MTP-PE), known as MEPACT(R) in Europe, for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
mifamurtide NDA amendment submission on hold until we complete our strategic review, which will allow us to operate into the third quarter of 2009.
a company focused on the development of innovative cancer products, including MEPACT(R) (known as mifamurtide in the United States), which was recently approved in Europe for the treatment of osteosarcoma, today announced that its financial statements for the fiscal year ended December 31, 2008, included in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2009, contain a going concern qualification from its independent registered public accounting firm.
IDM Pharma is currently developing mifamurtide (MEPACT in Europe) for the treatment of osteosarcoma, a rare bone cancer in children and young adults.
today announced that the Committee for Medicinal Products for Human Use (CHMP) formally adopted a positive opinion for mifamurtide (L-MTP- PE), known as MEPACT(R) in Europe, for the treatment of patients with non- metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
today announced that it met with representatives of the Committee for Medicinal Products for Human Use (CHMP) and Secretariat of the European Medicines Agency (EMEA) on September 25th, following the CHMP's September meeting where CHMP considered the Company's Marketing Authorization Application (MAA) for mifamurtide (L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.